Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 301 to 315 of 557 results for women's health

  1. Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.

  2. National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)

    NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital .

  3. Radiation dose monitoring software for medical imaging with ionising radiation (MIB127)

    NICE has developed a medtech innovation briefing (MIB) on radiation dose monitoring software for medical imaging with ionising radiation .

  4. Type 1 diabetes in adults: diagnosis and management (NG17)

    This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.

  5. Aortic valve reconstruction with processed bovine pericardium (IPG604)

    Evidence-based recommendations on aortic valve reconstruction with processed bovine pericardium. This involves replacing a damaged aortic valve with a new valve made from chemically treated cow pericardium.

  6. The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of

  7. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

  8. Faecal incontinence in adults (QS54)

    This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.

  9. Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)

    Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.

  10. Atogepant for preventing migraine (TA973)

    Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.

  11. HealthVCF for detecting vertebral compression fractures on CT scans (MIB267)

    NICE has developed a medtech innovation briefing (MIB) on HealthVCF for detecting vertebral compression fractures on CT scans .

  12. Information and support:- What information and support interventions are effective to help women with endometriosis deal with their symptoms and improve their quality of lives?

    support:- What information and support interventions are effective to help women with endometriosis deal with their symptoms and improve...

  13. Physical activity and the environment (NG90)

    This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.

  14. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

    Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

  15. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.